Selected research
Market Analysis & Forecast
Global Age-Related Macular Degeneration (AMD) Therapeutics Market Analysis and Forecast 2026-2032
Market perspective
The global Age-Related Macular Degeneration (AMD) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Age-Related Macular Degeneration (AMD) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Age-Related Macular Degeneration (AMD) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Age-Related Macular Degeneration (AMD) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Age-Related Macular Degeneration (AMD) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Age-Related Macular Degeneration (AMD) Therapeutics include Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd. and Bausch Health Companies, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Age-Related Macular Degeneration (AMD) Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Age-Related Macular Degeneration (AMD) Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Age-Related Macular Degeneration (AMD) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Age-Related Macular Degeneration (AMD) Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Age-Related Macular Degeneration (AMD) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Age-Related Macular Degeneration (AMD) Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Company
Novartis AG
Amgen Inc.
Regeneron Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.
Bausch Health Companies, Inc.
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Type
Wet AMD
Dry AMD
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Application
Clinic
Hospital
Research Institute
Other
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age-Related Macular Degeneration (AMD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Age-Related Macular Degeneration (AMD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age-Related Macular Degeneration (AMD) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Age-Related Macular Degeneration (AMD) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Age-Related Macular Degeneration (AMD) Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Age-Related Macular Degeneration (AMD) Therapeutics revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Wet AMD
- Dry AMD
Applications
- Clinic
- Hospital
- Research Institute
- Other
Companies covered
- Novartis AG
- Amgen Inc.
- Regeneron Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd.
- Bausch Health Companies, Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Age-Related Macular Degeneration (AMD) Therapeutics Market by Type
- 1.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Wet AMD
- 1.2.3 Dry AMD
- 1.3 Age-Related Macular Degeneration (AMD) Therapeutics Market by Application
- 1.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Clinic
- 1.3.3 Hospital
- 1.3.4 Research Institute
- 1.3.5 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Age-Related Macular Degeneration (AMD) Therapeutics Market Dynamics
- 2.1 Age-Related Macular Degeneration (AMD) Therapeutics Industry Trends
- 2.2 Age-Related Macular Degeneration (AMD) Therapeutics Industry Drivers
- 2.3 Age-Related Macular Degeneration (AMD) Therapeutics Industry Opportunities and Challenges
- 2.4 Age-Related Macular Degeneration (AMD) Therapeutics Industry Restraints
3 Global Growth Perspective
- 3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Perspective (2021-2032)
- 3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Growth Trends by Region
- 3.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2021-2026)
- 3.2.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players
- 4.1.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players (2021-2026)
- 4.1.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Key Players Headquarters & Area Served
- 4.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Players, Product Type & Application
- 4.5 Global Age-Related Macular Degeneration (AMD) Therapeutics Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market CR5 and HHI
- 4.6.3 2025 Age-Related Macular Degeneration (AMD) Therapeutics Tier 1, Tier 2, and Tier 3
5 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
- 5.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2032)
- 5.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2021-2032)
6 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
- 6.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2032)
- 6.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Novartis AG
- 7.1.1 Novartis AG Company Information
- 7.1.2 Novartis AG Business Overview
- 7.1.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2021-2026)
- 7.1.4 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 7.1.5 Novartis AG Recent Developments
- 7.2 Amgen Inc.
- 7.2.1 Amgen Inc. Company Information
- 7.2.2 Amgen Inc. Business Overview
- 7.2.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2021-2026)
- 7.2.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 7.2.5 Amgen Inc. Recent Developments
- 7.3 Regeneron Pharmaceuticals Inc.
- 7.3.1 Regeneron Pharmaceuticals Inc. Company Information
- 7.3.2 Regeneron Pharmaceuticals Inc. Business Overview
- 7.3.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2021-2026)
- 7.3.4 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 7.3.5 Regeneron Pharmaceuticals Inc. Recent Developments
- 7.4 F. Hoffmann-La Roche Ltd.
- 7.4.1 F. Hoffmann-La Roche Ltd. Company Information
- 7.4.2 F. Hoffmann-La Roche Ltd. Business Overview
- 7.4.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2021-2026)
- 7.4.4 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 7.4.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 7.5 Bausch Health Companies, Inc.
- 7.5.1 Bausch Health Companies, Inc. Company Information
- 7.5.2 Bausch Health Companies, Inc. Business Overview
- 7.5.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2021-2026)
- 7.5.4 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 7.5.5 Bausch Health Companies, Inc. Recent Developments
8 North America
- 8.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2021-2032)
- 8.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2032)
- 8.2.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2026)
- 8.2.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2027-2032)
- 8.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Type (2021-2032)
- 8.4 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2032)
- 8.4.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2026)
- 8.4.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2027-2032)
- 8.5 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Application (2021-2032)
- 8.6 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country
- 8.6.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2021-2026)
- 8.6.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2021-2032)
- 9.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2032)
- 9.2.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2026)
- 9.2.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2027-2032)
- 9.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Type (2021-2032)
- 9.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2032)
- 9.4.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2026)
- 9.4.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2027-2032)
- 9.5 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Application (2021-2032)
- 9.6 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country
- 9.6.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2021-2026)
- 9.6.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2021-2032)
- 10.2 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2032)
- 10.2.1 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2026)
- 10.2.2 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2027-2032)
- 10.3 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Type (2021-2032)
- 10.4 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2032)
- 10.4.1 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2026)
- 10.4.2 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2027-2032)
- 10.5 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2021-2032)
- 11.2 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2032)
- 11.2.1 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2026)
- 11.2.2 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2027-2032)
- 11.3 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Type (2021-2032)
- 11.4 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2032)
- 11.4.1 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2026)
- 11.4.2 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2027-2032)
- 11.5 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Application (2021-2032)
- 11.6 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country
- 11.6.1 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2021-2026)
- 11.6.3 Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2021-2032)
- 12.2 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2032)
- 12.2.1 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2026)
- 12.2.2 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2027-2032)
- 12.3 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Type (2021-2032)
- 12.4 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2032)
- 12.4.1 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2026)
- 12.4.2 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2027-2032)
- 12.5 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Application (2021-2032)
- 12.6 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country
- 12.6.1 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2021-2026)
- 12.6.3 SAMEA Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst